

The reappraisal of benzodiazepines in the treatment of

Expert Review of Neurotherapeutics

14, 1275-1286

DOI: [10.1586/14737175.2014.963057](https://doi.org/10.1586/14737175.2014.963057)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1885.	1.0	47
2	Need for a realistic appraisal of benzodiazepines. <i>World Psychiatry</i> , 2015, 14, 243-244.	4.8	17
3	Inconsistent Portrayal of Medication Dependence, Withdrawal and Discontinuation Symptoms in Treatment Guidelines for Anxiety Disorders. <i>Psychotherapy and Psychosomatics</i> , 2015, 84, 379-380.	4.0	13
4	Latest guidelines for the management of the anxiety disorders – a report from The International Anxiety Disorders Society Conference, Melbourne 2014. <i>Australasian Psychiatry</i> , 2015, 23, 388-391.	0.4	6
5	Generalized anxiety disorder: psychopharmacotherapy update on a common and commonly overlooked condition. <i>Australasian Psychiatry</i> , 2015, 23, 338-342.	0.4	9
6	Pharmacological treatment for generalized anxiety disorder in adults: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1669-1681.	0.9	61
7	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. <i>Pharmacological Reviews</i> , 2015, 67, 872-1004.	7.1	125
8	Benzodiazepine Intoxication and Withdrawal. <i>Hospital Medicine Clinics</i> , 2015, 4, 513-525.	0.2	2
9	Prescribing and Dispensing of Benzodiazepines. , 2016, , 283-292.		0
10	Benzodiazepines and Anxiety Disorders: From Laboratory to Clinic. , 2016, , .		2
11	Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse Events. <i>PLoS ONE</i> , 2016, 11, e0163224.	1.1	6
12	Use of benzodiazepines in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2016, 31, 27-33.	0.9	11
14	Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder?. <i>International Clinical Psychopharmacology</i> , 2016, 31, 347-352.	0.9	23
16	Sustained Use of Benzodiazepines and Escalation to High Doses in a Canadian Population. <i>Psychiatric Services</i> , 2016, 67, 1012-1018.	1.1	28
17	Antidepressants and benzodiazepines for panic disorder in adults. <i>The Cochrane Library</i> , 2016, 2016, CD011567.	1.5	20
18	Attitudes towards a maintenance (-agonist) treatment approach in high-dose benzodiazepine-dependent patients: a qualitative study. <i>Harm Reduction Journal</i> , 2016, 13, 1.	1.3	32
19	The importance of distinguishing between dependence and addiction in the context of long-term benzodiazepine use. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1111-1112.	1.3	2
20	The pattern of anxiolytic and hypnotic management by Australian general practice trainees. <i>Drug and Alcohol Review</i> , 2017, 36, 261-269.	1.1	8

#	ARTICLE	IF	CITATIONS
21	Morbid Anxiety: Identification and Treatment. Focus (American Psychiatric Publishing), 2017, 15, 136-143.	0.4	2
22	Relationship between the use of benzodiazepines and falls in older adults: A systematic review. Maturitas, 2017, 101, 17-22.	1.0	76
23	Does initial use of benzodiazepines delay an adequate pharmacological treatment? A multicentre analysis in patients with psychotic and affective disorders. International Clinical Psychopharmacology, 2018, 33, 140-146.	0.9	6
24	Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review. Psychotherapy and Psychosomatics, 2018, 87, 65-74.	4.0	56
25	Predictors of benzodiazepine use in a transdiagnostic sample of panic disorder, social anxiety disorder, and obsessive-compulsive disorder patients. Psychiatry Research, 2018, 262, 237-245.	1.7	4
26	Psychiatrists' treatment preferences for generalized anxiety disorder. Human Psychopharmacology, 2018, 33, e2643.	0.7	6
27	Insomnia in hospitalized psychiatric patients: prevalence and associated factors. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 969-975.	1.0	16
30	Phytol: A review of biomedical activities. Food and Chemical Toxicology, 2018, 121, 82-94.	1.8	198
31	Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment. Journal of Psychopharmacology, 2019, 33, 1340-1351.	2.0	23
32	Photopotential of the GABA _A receptor with caged diazepam. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21176-21184.	3.3	10
33	Exploring characteristics associated with first benzodiazepine prescription in patients with affective disorders and related diagnoses. Human Psychopharmacology, 2019, 34, e2695.	0.7	6
34	Prevalence of and pathways to benzodiazepine use in Brazil: the role of depression, sleep, and sedentary lifestyle. Revista Brasileira De Psiquiatria, 2019, 41, 44-50.	0.9	18
35	S-ketamine reduces marble burying behaviour: Involvement of ventromedial orbitofrontal cortex and AMPA receptors. Neuropharmacology, 2019, 144, 233-243.	2.0	20
36	Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety. World Journal of Biological Psychiatry, 2019, 20, 514-518.	1.3	16
37	Benzodiazepine ingestion as a way to die by suicide and related safety: the case of an elderly patient. Aging Clinical and Experimental Research, 2019, 31, 287-289.	1.4	3
38	Sleep disturbance in PTSD and other anxiety-related disorders: an updated review of clinical features, physiological characteristics, and psychological and neurobiological mechanisms. Neuropsychopharmacology, 2020, 45, 55-73.	2.8	105
39	Zebrafish and mouse models for anxiety evaluation – A comparative study with xanthotoxin as a model compound. Brain Research Bulletin, 2020, 165, 139-145.	1.4	13
40	Absence of definitive scientific evidence that benzodiazepines could hinder the efficacy of exposure-based interventions in adults with anxiety or posttraumatic stress disorders: A systematic review of randomized clinical trials. Depression and Anxiety, 2020, 37, 1231-1242.	2.0	4

#	ARTICLE	IF	CITATIONS
41	Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland. <i>JAMA Network Open</i> , 2020, 3, e2019029.	2.8	24
42	Perceptions, clinical characteristics, and other factors associated with prolonged and high daily dose of benzodiazepine use among patients with anxiety or depressive disorders. <i>Journal of Affective Disorders</i> , 2020, 271, 215-223.	2.0	5
43	Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 283-306.	4.0	132
44	Threat-sensitivity in affective disorders: A case-control study. <i>Journal of Affective Disorders</i> , 2020, 266, 595-602.	2.0	1
45	Animal Models in Anxiety Research. , 2021, , 205-225.		0
46	Late-Life Anxiety. , 2021, , 226-240.		0
47	Relationship between benzodiazepine prescription, aggressive behavior, and behavioral disinhibition: a retrospective study in a Swiss prison. <i>Harm Reduction Journal</i> , 2021, 18, 58.	1.3	1
48	Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: A systematic review and network meta-analysis. <i>Asian Journal of Psychiatry</i> , 2021, 60, 102664.	0.9	4
49	Immediate retrograde amnesia induced by midazolam: A prospective, non-randomised cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14402.	0.8	5
50	Usages et bon usage des benzodiazépines anxiolytiques et hypnotiques. <i>Annales Medico-Psychologiques</i> , 2021, 179, 748-756.	0.2	4
51	Current and Novel Psychopharmacological Drugs for Anxiety Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1191, 347-365.	0.8	55
52	Role of Benzodiazepines in Anxiety Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1191, 367-388.	0.8	45
53	TSPO, a Mitochondrial Outer Membrane Protein, Controls Ethanol-Related Behaviors in <i>Drosophila</i> . <i>PLoS Genetics</i> , 2015, 11, e1005366.	1.5	17
54	Are Bioequivalents Really Equal?: Generic Substitution in the Context of Mental Illness. <i>Indiana Health Law Review</i> , 2018, 12, 281-326.	0.1	2
55	Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System. <i>Current Pharmaceutical Design</i> , 2015, 21, 3325-3342.	0.9	7
56	NOVEL MEASURES OF BENZODIAZEPINE & Z-DRUG UTILISATION TRENDS IN A CANADIAN PROVINCIAL ADULT POPULATION (2001-2016). <i>Canadian Journal of Clinical Pharmacology</i> , 2019, 26, e22-e38.	1.1	23
57	Treatment of anxiety disorders. <i>Dialogues in Clinical Neuroscience</i> , 2017, 19, 93-107.	1.8	420
58	The Use of Benzodiazepines in Patients with Methadone Treatment. <i>Makedonsko Medicinsko Elektronsko Spisanie</i> , 0, 2015, 1-262.	0.0	0

#	ARTICLE	IF	CITATIONS
59	Staging of Panic Disorder: Implications for Neurobiology and Treatment. , 2016, , 113-125.		0
60	Effects of ascorbic acid on anxiety state and affect in a non-clinical sample. <i>Acta Neurobiologiae Experimentalis</i> , 2017, 77, 362-372.	0.4	10
61	The Development of Therapeutic Drugs for Insomnia. <i>Hans Journal of Medicinal Chemistry</i> , 2017, 05, 1-10.	0.0	0
62	Panico: nosografia di un'entità, clinica di un disturbo. <i>Mission</i> , 2017, , .	0.1	0
64	Role and place of benzodiazepines in pharmacotherapy of posttraumatic stress disorder. <i>International Neurological Journal</i> , 2018, .	0.2	1
65	Effect of <i>Salvia officinalis</i> L. and <i>Rosmarinus officinalis</i> L. leaves extracts on anxiety and neural activity. <i>Bioinformation</i> , 2019, 15, 172-178.	0.2	9
66	Escitalopram and lorazepam differentially affect nesting and open field behaviour in deer mice exposed to an anxiogenic environment. <i>Neuroscience Research</i> , 2022, 177, 85-93.	1.0	6
67	Management of Acute Psychiatric Problems. , 2020, , 537-543.		0
68	Psychosomatic disorders: causes, development mechanisms, clinical manifestations and feasibilities of autopsychocorrection. <i>Proceedings of the National Academy of Sciences of Belarus, Medical Series</i> , 2020, 17, 101-121.	0.2	0
69	Representation of Benzodiazepines in Treatment Guidelines: The Paradox of Undesirable Objectivity. <i>Psychotherapy and Psychosomatics</i> , 2022, 91, 295-299.	4.0	5
70	Anxiolytic Effect of <i>Anthemis nobilis</i> L. (Roman Chamomile) and <i>Citrus reticulata</i> Blanco (Tangerine) Essential Oils Using the Light-Dark Test in Zebrafish (<i>Danio rerio</i>). <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
71	Sexually dimorphic effects of prenatal diazepam exposure on respiratory control and the monoaminergic system of neonate and young rats. <i>Pflugers Archiv European Journal of Physiology</i> , 2022, 474, 1185-1200.	1.3	4
72	Anxiolytic effect of <i>Anthemis nobilis</i> L. (roman chamomile) and <i>Citrus reticulata</i> Blanco (tangerine) essential oils using the light-dark test in zebrafish (<i>Danio rerio</i>). <i>Journal of Ethnopharmacology</i> , 2022, 298, 115580.	2.0	5
73	Eficácia dos benzodiazepínicos no tratamento de transtornos ansiosos: uma revisão de literatura. , 2022, 101, .	0.0	0
74	Benzodiazepine-Receptor Agonist Utilization in Outpatients with Anxiety Disorder: A Retrospective Study Based on Electronic Healthcare Data from a Large General Tertiary Hospital. <i>Healthcare (Switzerland)</i> , 2023, 11, 554.	1.0	1